Acute pancreatitis following brentuximab vedotin therapy for refractory Hodgkin lymphoma: a case report.
CRS4, Biomedicine Sector, Center for Advanced Studies, Research and Development in Sardinia Technology Park Polaris, Building 1 Piscina Manna, Pula, 09010, Cagliari, Italy, silvanaurru@crs4.it.
S A M
SA
Urru
E
E
Mariotti
P
P
Carta
S
S
Massidda
M
M
Marcias
R
R
Murru
P
P
Sanna
E
E
Angelucci
D000208:Acute Disease; D000368:Aged; D000079963:Brentuximab Vedotin; D006689:Hodgkin Disease / Q000188:drug therapy*; D006801:Humans; D018796:Immunoconjugates / Q000009:adverse effects*; D008297:Male; D010195:Pancreatitis / Q000139:chemically induced*
D018796:Immunoconjugates; D000079963:Brentuximab Vedotin